Sebastien A. Burel

1.7k total citations
23 papers, 1.2k citations indexed

About

Sebastien A. Burel is a scholar working on Molecular Biology, Immunology and Hematology. According to data from OpenAlex, Sebastien A. Burel has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Immunology and 6 papers in Hematology. Recurrent topics in Sebastien A. Burel's work include RNA Interference and Gene Delivery (7 papers), Immune Response and Inflammation (5 papers) and Acute Myeloid Leukemia Research (4 papers). Sebastien A. Burel is often cited by papers focused on RNA Interference and Gene Delivery (7 papers), Immune Response and Inflammation (5 papers) and Acute Myeloid Leukemia Research (4 papers). Sebastien A. Burel collaborates with scholars based in United States, Sweden and Switzerland. Sebastien A. Burel's co-authors include Dong‐Er Zhang, Scott P. Henry, Liming Zhou, Nari Harakawa, Hiromi Iwasaki, Koichi Akashi, Youzhong Yuan, Christopher J. Hetherington, Toshihiro Miyamoto and Eric Lagasse and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Molecular and Cellular Biology.

In The Last Decade

Sebastien A. Burel

21 papers receiving 1.2k citations

Peers

Countries citing papers authored by Sebastien A. Burel

Since Specialization

Citations

This map shows the geographic impact of Sebastien A. Burel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sebastien A. Burel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sebastien A. Burel more than expected).

Fields of papers citing papers by Sebastien A. Burel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sebastien A. Burel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sebastien A. Burel. The network helps show where Sebastien A. Burel may publish in the future.

Co-authorship network of co-authors of Sebastien A. Burel

This figure shows the co-authorship network connecting the top 25 collaborators of Sebastien A. Burel. A scholar is included among the top collaborators of Sebastien A. Burel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sebastien A. Burel. Sebastien A. Burel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system 2025 ·Nucleic Acids Research ·(unknown), (unknown), Curt Mazur, (unknown), Oleksandr Platoshyn, (unknown), (unknown), (unknown), Sebastien A. Burel, (unknown), Thomas A. Zanardi, (unknown), (unknown), Scott P. Henry, Eric E. Swayze, Berit Powers, Holly Kordasiewicz	0
2	Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations 2025 ·Nucleic Acid Therapeutics ·Patrik Andersson, Sebastien A. Burel, Heather Estrella, Jeffrey W.-D. Foy, Peter Hagedorn, (unknown), Scott P. Henry, Jean-Christophe Hoflack, Erle M. Holgersen, Arthur A. Levin, (unknown), Adam Pavlı́c̀ek, (unknown), Utsav Saxena	3
3	Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events 2023 ·Clinical and Translational Science ·(unknown), Sebastien A. Burel, (unknown), Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker	4
4	Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells 2022 ·Nucleic Acid Therapeutics ·Sebastien A. Burel, Todd Machemer, Brenda F. Baker, T. Jesse Kwoh, (unknown), Husam S. Younis, Scott P. Henry	14
5	Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab Cells 2022 ·Nucleic Acid Therapeutics ·(unknown), (unknown), Todd Machemer, (unknown), Sagar Damle, Scott P. Henry, Sebastien A. Burel	12
6	Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide–Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6 2021 ·Journal of Pharmacology and Experimental Therapeutics ·Thomas A. Zanardi, (unknown), Laura Boone, (unknown), Yanfeng Wang, Sebastien A. Burel, (unknown), Mariam Aghajan, Shuling Guo, Scott P. Henry	7
7	Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides 2021 ·Nucleic Acids Research ·Brooke A. Anderson, Graeme C. Freestone, Audrey Low, (unknown), William J. Drury, Michael E. Østergaard, Michael T. Migawa, Michael Fazio, Wei Wan, Andrés Berdeja, (unknown), Sebastien A. Burel, Timothy A. Vickers, Stanley T. Crooke, Eric E. Swayze, Xue‐hai Liang, Punit P. Seth	89
8	Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia 2020 ·Nucleic Acid Therapeutics ·(unknown), Brian R. Curtis, Lijiang Shen, Eugene Schneider, Joseph A. Tami, (unknown), Sebastien A. Burel, Bruce L. Tai, Todd Machemer, T. Jesse Kwoh, Shuting Xia, Sanford J. Shattil, Joseph L. Witztum, Jeffery A. Engelhardt, Scott P. Henry, Brett P. Monia, Steven G. Hughes	26
9	Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 Data 2020 ·ESC Heart Failure ·Nicholas J. Viney, Shuling Guo, Bruce L. Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien A. Burel, Sue Murray, Gustavo Büchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia	65
10	Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2′- O -Methoxyethyl Antisense Oligonucleotide 2019 ·Nucleic Acid Therapeutics ·Elaine Pirie, (unknown), Wuxia Fu, Shayoni Ray, Calvin Pan, (unknown), (unknown), Sebastien A. Burel, Padma Kumar Narayanan, Rosanne M. Crooke, Richard Lee	5
11	Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2ʹ-MOE-Modified Antisense Oligonucleotide 2018 ·Toxicological Sciences ·(unknown), Lijiang Shen, Brian R. Curtis, Mario A. Bourdon, John P. Nolan, Shipra Gupta, (unknown), Fangli Zhou, (unknown), (unknown), Sarah Greenlee, Sebastien A. Burel, (unknown), (unknown), Scott P. Henry	26
12	Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice 2018 ·Toxicologic Pathology ·Tae‐Won Kim, (unknown), (unknown), Jeffery A. Engelhardt, (unknown), Noah Post, John Matson, (unknown), Sebastien A. Burel, Scott P. Henry	0
13	The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides 2017 ·Nucleic Acid Therapeutics ·(unknown), (unknown), (unknown), Armand Soriano, Lawrence Bai, Todd Machemer, Xiaokun Xiao, Shuling Guo, Gene Hung, Husam S. Younis, C. Frank Bennett, Scott P. Henry, Theodore J. Yun, Sebastien A. Burel	21
14	Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers 2016 ·Molecular Therapy ·Stanley T. Crooke, Brenda F. Baker, T. Jesse Kwoh, Wei Cheng, (unknown), Shuting Xia, Nelson R. Salgado, Huynh‐Hoa Bui, Christopher E. Hart, Sebastien A. Burel, Husam S. Younis, Richard S. Geary, Scott P. Henry, Sanjay Bhanot	93
15	Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts 2015 ·Nucleic Acids Research ·Sebastien A. Burel, Christopher E. Hart, (unknown), (unknown), Todd Machemer, Melanie Katz, Andy Watt, Huynh‐Hoa Bui, Husam S. Younis, Mahyar Sabripour, Susan M. Freier, Gene Hung, (unknown), Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, C. Frank Bennett, Stanley T. Crooke, Scott P. Henry	148
16	Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Sebastien A. Burel, Todd Machemer, (unknown), Hiroki Kato, (unknown), Sarah Greenlee, (unknown), William A. Gaarde, Gene Hung, Raechel Peralta, Susan M. Freier, Scott P. Henry	25
17	Non-CpG-Containing Antisense 2′-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid Differentiation Factor 88 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Joseph J. Senn, Sebastien A. Burel, Scott P. Henry	70
18	AML1 and AML1 Fusion Protein AML1-ETO in Myeloid Gene Regulation and Leukemogenesis 2001 ·Blood Cells Molecules and Diseases ·Dong‐Er Zhang, Sebastien A. Burel, Liming Zhou, Christopher J. Hetherington, Youzhong Yuan	3
19	AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations 2001 ·Proceedings of the National Academy of Sciences ·Youzhong Yuan, Liming Zhou, Toshihiro Miyamoto, Hiromi Iwasaki, Nari Harakawa, Christopher J. Hetherington, Sebastien A. Burel, Eric Lagasse, Irving L. Weissman, Koichi Akashi, Dong‐Er Zhang	324
20	Dichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation 2001 ·Molecular and Cellular Biology ·Sebastien A. Burel, Nari Harakawa, Liming Zhou, Thomas Pabst, Daniel G. Tenen, Dong‐Er Zhang	118

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact